Hagop M. Kantarjian

Specialty: Leukemia Research

Location: United States

Tier: TITAN

H-Index: 320

Years Active: 0

Hospital Affiliations

• MD Anderson Cancer Center - Faculty

Key Publications

1. "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms." - Leukemia (2022)
2. "Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial." - Lancet Haematol (2023)
3. "Acute myeloid leukemia management and research in 2025." - CA Cancer J Clin (2025)
4. "PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia." - Nat Genet (2019)
5. "Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia." - J Clin Oncol (2021)

Knowledge Graph Relationships

Hagop M. Kantarjian is a Leukemia Research specialist affiliated with MD Anderson Cancer Center. Authored 5 scholarly articles.